| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/03/2008 | CA2631506A1 Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| 01/03/2008 | CA2614389A1 Extended release solid pharmaceutical composition containing carbidopa and levodopa |
| 01/02/2008 | EP1873527A1 Method for identifying CRMP modulators |
| 01/02/2008 | EP1873259A1 RNA interference is mediated by 21 and 22nt small RNAs |
| 01/02/2008 | EP1873258A1 Detection of ESR1 amplification in breast cancer |
| 01/02/2008 | EP1873240A1 hTERT GENE EXPRESSION REGULATORY GENE |
| 01/02/2008 | EP1873204A1 Polymeric pharmaceutical agent for treatment of cancer and process for production of the same |
| 01/02/2008 | EP1873159A1 Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 01/02/2008 | EP1873158A1 Crystals of morphinan derivative and process for producing the same |
| 01/02/2008 | EP1873157A1 Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 01/02/2008 | EP1873155A1 Inhibitors of the HIV integrase enzyme |
| 01/02/2008 | EP1873154A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVE OR MEDICALLY ACCEPTABLE SALT THEREOF |
| 01/02/2008 | EP1873153A1 Heterocyclic compound |
| 01/02/2008 | EP1873150A1 Fluorinated indoleamides useful as ligands of the ORL-1 receptor |
| 01/02/2008 | EP1873148A1 pharmaceutical compositions containing crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid |
| 01/02/2008 | EP1873147A1 Phthalazinone derivative and pharmaceutical comprising the same |
| 01/02/2008 | EP1873144A1 Fused heterocyclic compound |
| 01/02/2008 | EP1873141A1 Calcium bis[2s)-3-[3-(2s)-3-(4-chloro-2-cyanophenoxy)-2- fluoropropoxy¨phenyl]-2-isopropoxypropionate] and intermediate thereof |
| 01/02/2008 | EP1873140A1 New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them |
| 01/02/2008 | EP1873139A1 New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them |
| 01/02/2008 | EP1872798A1 Intestinal absorptive anti-tumor agent |
| 01/02/2008 | EP1872797A2 Treatment of cardiovascular and related pathologies |
| 01/02/2008 | EP1872796A1 Transdermal preparation for external use containing nonsteroidal antiinflammatory/analgesic agent |
| 01/02/2008 | EP1872795A1 Therapeutic agent for irritable bowel syndrome |
| 01/02/2008 | EP1872794A1 Nasal vaccine |
| 01/02/2008 | EP1872790A1 New formulation for increasing bioavailability of neurturin |
| 01/02/2008 | EP1872787A1 Use of defibrotide for the inhibition of heparanase |
| 01/02/2008 | EP1872786A1 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
| 01/02/2008 | EP1872785A1 pharmaceutical composition comprising condensed indole compound |
| 01/02/2008 | EP1872784A1 Medicinal preparation for percutaneous absorption |
| 01/02/2008 | EP1872783A1 Therapeutic agent for corneal/conjunctival disorder |
| 01/02/2008 | EP1872782A1 Drug for treating or diagnosing vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation |
| 01/02/2008 | EP1872781A1 Combined pharmaceutical preparation for treatment of type 2 diabetes |
| 01/02/2008 | EP1872780A2 Omega-Phenyloctanamides as therapeutic compounds |
| 01/02/2008 | EP1872779A1 Stable multiparticulate pharmaceutical composition comprising tri-and tetracyclic antidepressants |
| 01/02/2008 | EP1872778A1 Stable pharmaceutical composition with rabeprazole sodium |
| 01/02/2008 | EP1872777A1 Pharmaceutical composition comprising tetrahydrolipstatin |
| 01/02/2008 | EP1872776A2 Mousse composition |
| 01/02/2008 | EP1872775A1 Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
| 01/02/2008 | EP1872774A1 A pharmaceutical composition adapted for oral transmucosal administration comprising sex hormone and its use |
| 01/02/2008 | EP1872772A1 Use of biotin or a biotin derivative for lightening skin and treating age spots |
| 01/02/2008 | EP1872668A1 Nutrient composition |
| 01/02/2008 | EP1871890A2 Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
| 01/02/2008 | EP1871786A1 Peptide vaccine for influenza virus |
| 01/02/2008 | EP1871777A1 (1, 10b-dihydro-2-(aminoalkyl- phenyl)-5h-pyraz0l0 [1,5-c] [1,3] benz0xazin-5-yl) phenyl methanone derivatives as hiv viral repliation inhibitors |
| 01/02/2008 | EP1871776A2 Fused thieno[2,3-b]pyridine and thiazolo[5,4-b]pyridine compounds for inhibiting ksp kinesin activity |
| 01/02/2008 | EP1871773A1 N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| 01/02/2008 | EP1871771A1 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors |
| 01/02/2008 | EP1871769A2 Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,their intermediates and crystalline salts thereof |
| 01/02/2008 | EP1871768A1 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
| 01/02/2008 | EP1871766A1 Antifungal triazole derivatives |
| 01/02/2008 | EP1871763A1 SUBSTITUTED ARYL 1.4-PYRAZlNE DERIVATIVES |
| 01/02/2008 | EP1871762A2 Subtituted heteroaryl cb1 antagonists |
| 01/02/2008 | EP1871761A2 Spirocyclic heterocyclic derivatives and methods of their use |
| 01/02/2008 | EP1871759A1 Benzodioxane and benzodioxolane derivatives and uses thereof |
| 01/02/2008 | EP1871758A1 Aminoalkyl-amidomethyl-substituted 2- (4-sulphonylamino) -3-hydroxy-3 , 4-dihydro-2h-cromen-6-yl derivatives and their use as potassium channel blockers |
| 01/02/2008 | EP1871756A1 Benzo (b) cycloprop (d) pyran-2-(1h)-one derivatives |
| 01/02/2008 | EP1871755A1 Dihydrobenzofuran derivatives and uses thereof |
| 01/02/2008 | EP1871754A1 Dihydrobenzofuran derivatives and uses thereof |
| 01/02/2008 | EP1871753A1 Preparation of taxanes from 9-dihydro-13-acetylbaccatin iii |
| 01/02/2008 | EP1871752A1 Amidopropoxyphenyl orexin receptor antagonists |
| 01/02/2008 | EP1871749A1 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands |
| 01/02/2008 | EP1871748A1 (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines |
| 01/02/2008 | EP1871743A1 Antiparasitic compounds |
| 01/02/2008 | EP1871742A1 Preparation of ý2-methyl-5-phenyl-3-(piperazin-1-ylmethyl)¨pyrrole derivatives |
| 01/02/2008 | EP1871741A2 Substituted azetidinones |
| 01/02/2008 | EP1871739A1 Compounds which inhibit beta-secretase activity and methods of use thereof |
| 01/02/2008 | EP1871738A2 N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use |
| 01/02/2008 | EP1871734A2 Preparation of sevoflurane with negligible water content |
| 01/02/2008 | EP1871426A2 Small activating rna molecules and methods of use |
| 01/02/2008 | EP1871420A2 Methods of facilitating cell survival using neurotrophin mimetics |
| 01/02/2008 | EP1871414A1 Method for traeting inflammatory bowel disease (ibd) by an anti-cd20 antibody |
| 01/02/2008 | EP1871400A2 Uronic acid and probiotics |
| 01/02/2008 | EP1871397A1 Health-related liquid compositions comprising glycosylaminoglycan |
| 01/02/2008 | EP1871396A1 Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor |
| 01/02/2008 | EP1871395A1 Garlic extract and chitosan compositions, and uses thereof |
| 01/02/2008 | EP1871394A2 Anti-inflammatory and/or analgesic composition for the intestine comprising branched maltodextrins |
| 01/02/2008 | EP1871393A2 Acarbose methods and formulations for treating chronic constipation |
| 01/02/2008 | EP1871392A1 Modulating angiogenesis with nod factors such as glucosamine oligosaccharides |
| 01/02/2008 | EP1871391A2 Endogenous retrovirus and proteins encoded by env as a target for cancer treatment |
| 01/02/2008 | EP1871390A1 S-adenosyl-l-methionine for regulating behavioral disorders in pets |
| 01/02/2008 | EP1871389A2 Skin enrichment using coq10 as the delivery system |
| 01/02/2008 | EP1871388A2 Methods of protection from oxidative stress |
| 01/02/2008 | EP1871387A1 Intravenous formulations of pyridoxal 5'-phosphate and method of preparation |
| 01/02/2008 | EP1871386A1 Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof |
| 01/02/2008 | EP1871385A1 Methods for treating visual disorders |
| 01/02/2008 | EP1871384A2 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| 01/02/2008 | EP1871383A2 Device and methods for treating paranasal sinus conditions |
| 01/02/2008 | EP1871382A2 Methods for the treatment of central nervous system injury via a tapered administration of progesterone |
| 01/02/2008 | EP1871381A2 Therapeutic substituted cyclopentanones |
| 01/02/2008 | EP1871380A1 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders |
| 01/02/2008 | EP1871379A2 Cyanoarylamines |
| 01/02/2008 | EP1871378A1 Uses of 2-phenyl-substituted imidazotriazinone derivatives for treating pulmonary hypertension |
| 01/02/2008 | EP1871377A1 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
| 01/02/2008 | EP1871376A2 Inhibitors of akt activity |
| 01/02/2008 | EP1871375A2 Carboline derivatives useful in the treatment of cancer |
| 01/02/2008 | EP1871374A2 2,3 substituted pyrazine sulfonamides as inhibitors of crth2 |
| 01/02/2008 | EP1871373A1 Piperazinyl substituted cyclohexane 1,4-diamines |
| 01/02/2008 | EP1871372A1 Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain |
| 01/02/2008 | EP1871371A2 Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients |